ClinicalTrials.gg
TerminatedNCT07237295CRx-KUpdated Nov 5, 2026

CommunityRx-Kidney Health

An interventional study of CommunityRx-Kidney Health in Chronic Kidney Disease (Stages 1-4), sponsored by University of North Carolina, Chapel Hill. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Health services research

Why this study was terminated
Unanticipated operational challenges. No safety concerns.
Updated Nov 5, 2026Now TerminatedNow Active, not recruiting+4 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In the United States, the burden of chronic kidney disease (CKD) rests disproportionately on rural communities. This study evaluates the implementation and effectiveness of CommunityRx-Kidney Health (CRx-K); this health information technology intervention integrates medical, social, and self-care resources to improve CKD management in rural eastern North Carolina. Through a partnership among local primary care centers, community organizations, and researchers, CRx-K will strengthen rural care networks, improve CKD management, and enhance the well-being of rural communities.

Read the detailed description

Approximately one in seven adults in the United States lives with chronic kidney disease (CKD). CKD typically worsens with time and, in its final stage, can result in kidney failure. Contextual factors in rural, eastern North Carolina communities impede optimal management of CKD multimorbidity. In these communities, geographical barriers to medical care, dwindling resources, and underdeveloped health infrastructure have worsened CKD outcomes. CommunityRx-Kidney Health (CRx-K) is an evidence-based, low-intensity, health information technology-driven intervention designed to support CKD management in rural eastern North Carolina. CRx-K integrates medical (e.g., blood pressure and glucose monitoring, eye and foot care), social (food, housing, transportation), and self-care (weight and stress management, exercise) resources. CRx-K comprises three components: brief education on integrated CKD needs, a personalized community resource referral list (HealtheRx), and clinic navigator-led, longitudinal support (12 months) for CKD patients in our trial. Our multidisciplinary, community-engaged research team will test the effects of CRx-K through three related aims.

This pragmatic individual-randomized, two-arm, single-blind trial in 35 rural primary care clinics in 16 rural eastern North Carolina counties (n=634 adults with CKD) assesses the effect of CRx-K on acute healthcare utilization (primary outcome), self-efficacy for finding resources, knowledge and sharing of integrated care resources, resource use, number of unmet needs over time, ambulatory care utilization, and health-related quality of life. The researchers hypothesize that 12-month acute healthcare utilization will differ between participants receiving CRx-K and those receiving usual care.

02

Conditions studied

  • Chronic Kidney Disease (Stages 1-4)

Keywords

  • Chronic disease management
  • Community resource referral
  • Health-related social needs
  • Healthcare services
  • Kidney health
  • Longitudinal navigation support
  • Rural health
  • Self-efficacy
03

In context

Renal Insufficiency, Chronic

3,090 studies on the registry are indexed under Renal Insufficiency, Chronic; 698 are open to participants now.

This study's enrollment of 23 is below the median of 73 across 2,157 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

University of North Carolina, Chapel Hill is the lead sponsor of 1,372 studies on the registry; 133 are open to participants now.

Of its 161 completed or terminated interventional studies of FDA-regulated products, 139 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic kidney disease defined as ≥1 ICD-10 CKD codes (excluding end-stage kidney disease) or CKD biomarkers (estimated ≤ 60 ml/min, albuminuria ≥30 mg/24h)
  • At least one clinic visit at Goshen Medical Center in 12 months before enrollment

Exclusion criteria

Exclusion Criteria:

  • Limited (e.g., advanced cancer, end-stage liver disease, hospice)
  • Active cancer treatment
  • Living in a skilled nursing facility
  • Dementia/other significant cognitive impairment/inability to participate in the process
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Intervention + usual care

    This arm will receive the intervention in addition to usual care.

    Behavioral: CommunityRx-Kidney Health

  • No intervention
    Usual care only

    This arm will not receive the intervention.

Interventions

  • BehavioralCommunityRx-Kidney Health

    CommunityRx-Kidney Health (CRx-K) is an evidence-based, low-intensity, health information technology-driven intervention designed to support chronic kidney disease management in rural eastern North Carolina. CRx-K integrates medical (e.g., blood pressure and glucose monitoring, eye and foot care), social (food, housing, transportation), and self-care (weight and stress management, exercise) resources. CRx-K comprises three components: brief education on integrated chronic kidney disease needs, a personalized community resource referral list (HealtheRx), and clinic navigator-led, longitudinal support (12 months) for chronic kidney disease patients.

    Also known as: CRx-K

06

What researchers measure

Primary outcomes

  1. Acute healthcare utilization

    Acute healthcare utilization is measured as the sum of self-reported 911 calls, ambulance visits, emergency room visits, urgent care visits, and hospital admissions across the 12-month follow-up period.

    Time frame: 12 months

Secondary outcomes

  1. Ambulatory healthcare utilization

    Number of ambulatory (physician office) visits across the 12-month follow-up period is self-reported based on responses to an item originally used in DIAMOND RCT: "How many times have you seen a physician for an office visit?"

    Time frame: 12 months

  2. Self-efficacy for finding social and self-care resources

    Self-efficacy for finding social and self-care resources is measured using an item developed from Bandura's self-efficacy theory and used in prior CommunityRx trials: "How confident are you in your ability to find resources in your community that help you manage your health?" Responses will be assessed on a 4-point Likert scale ranging from '1' (not at all confident) to '4' (completely confident).

    Time frame: 6 months, 12 months

  3. Attitudes about social and self-care resources

    Attitude about social and self-care resources are measured using a self-report Likert item adapted and tested in prior CommunityRx studies: "Your community has the resources you need to manage your health." Response options range from '1' (strongly agree) to '5' (strongly disagree).

    Time frame: 6 months, 12 months

  4. Knowledge of social and self-care resources

    Knowledge of social and self-care resources is measured using a self-reported item adapted and tested in prior CommunityRx studies and repeated for 12 resource types: "Do you know of places in your community that offer \[resource type\]?" The research team will report the sum of resource types that participants endorse knowledge of.

    Time frame: 6 months, 12 months

  5. Use of social and self-care resources

    Use of social and self-care resources (for which a participant reports knowledge) is measured using a self-report item adapted and tested in prior CommunityRx studies and repeated for 12 resource types: "Have you received services from places like this for you or your household in the past 3 months?" The research team will report the total number of resource types that participants endorse using.

    Time frame: 6 months, 12 months

  6. Unmet social and self-care needs

    Unmet social and self-care needs are measured using self-report items adapted and tested in prior CommunityRx studies and repeated for 12 resource types. Participants who report not having used a resource type in the past 3 months respond to: "Is this a service that you or your household needs?" Participants who report having used a resource type in the past 3 months respond to: "Do these places meet your \[resource type\] needs?" The research team will report the total number of resource types that participants endorse needing.

    Time frame: 6 months, 12 months

  7. Sharing of information about social and self-care resources

    Sharing of social and self-care resources (for which a participant reports knowledge) is measured using a self-report item adapted and tested in prior CommunityRx studies and repeated for 12 resource types: "Did you tell anyone about places like this in the past 3 months?" The research team will report the sum of resource types that participants endorse sharing.

    Time frame: 6 months, 12 months

  8. Health-related quality of life

    The 10-item Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 assesses general health-related quality of life and is self-reported. Response options are presented as nine 5-point and one 11-point Likert scales. Higher raw sum scores indicate greater health-related quality-of-life.

    Time frame: 6 months, 12 months

07

Study locations

1 site
  • Goshen Medical Center
    Beulaville, North Carolina 28518, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual data that supports the results will be shared provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with The University of North Carolina at Chapel Hill.

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: Beginning 9 and continuing for 36 months following publication

Access criteria: Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with The University of North Carolina at Chapel Hill

09

Updates

2 registry updates since Sep 25, 2026
Status
Recruiting→Active, not recruiting→Terminated Unanticipated operational challenges. No safety concerns.
changed Oct 6, 2026 · changed Nov 5, 2026
Primary completion
Jun 2028→Sep 8, 2026 (actual)
Oct 6, 2026
Study completion
Jun 2028→Sep 8, 2026 (actual)
moved 2 times, Oct 6, 2026 – Nov 5, 2026
Enrollment
634 (estimated)→23 (actual)
Oct 6, 2026
Documents
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Active, not recruiting→Terminated
    Why stopped Unanticipated operational challenges. No safety concerns.
    Documents Informed consent form ↗ posted
    Study completion Oct 2026→Sep 8, 2026 (now actual)
    + 1 other change: contact details
  2. Oct 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 2028→Sep 8, 2026 (now actual)
    Study completion Jun 2028→Oct 2026
    Enrollment 634 (estimated)→23 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07237295
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Goshen Medical Center, James McFarlin Community Development, Inc., Johns Hopkins University, Project GRACE, Project Momentum, Inc., UniteUs, University of Chicago
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Apr 13, 2026
Primary completion
Sep 8, 2026
Completion
Sep 8, 2026
Last update
Nov 5, 2026

Study contacts

Gaurav J Dave, MBBS, DrPH, MPH
principal investigator · University of North Carolina, Chapel Hill
Abhijit V Kshirsagar, MD, MPH
principal investigator · University of North Carolina, Chapel Hill
Stacy Tessler Lindau, MD, MA
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion